As Puma Biotechnology INC (PBYI) Stock Price Declined, Shareholder Brookside Capital Management LLC Has Upped Its Holding

January 22, 2018 - By Jan Rainey

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It increased, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Northwestern Mutual Wealth Management reported 0% stake. First Trust Advsrs Lp accumulated 4,586 shares. Orbimed Ltd Limited Liability Company reported 2.43M shares. C Ww Group Incorporated A S, a Denmark-based fund reported 23,792 shares. Blackrock stated it has 1.81M shares. Strs Ohio has 2,700 shares. Ascend Lc reported 716,717 shares stake. J Goldman LP has 0.1% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Tekla Cap Management Ltd Liability Corp invested in 105,495 shares. Brinker Capital Inc holds 0.01% or 1,790 shares in its portfolio. Virginia Retirement Et Al holds 12,200 shares. Deutsche Bancorporation Ag holds 0.05% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 603,908 shares. Credit Suisse Ag has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Goldman Sachs Group Incorporated has 0.01% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Voya Ltd Liability Corporation holds 0.08% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 300,424 shares.

Since September 6, 2017, it had 0 buys, and 2 sales for $3.30 million activity.

Bain Capital increased its stake in Puma Biotechnology Inc (PBYI) by 94.07% based on its latest 2017Q3 regulatory filing with the SEC. Brookside Capital Management Llc bought 318,882 shares as the company’s stock declined 6.09% while stock markets rallied. The hedge fund run by Bain Capital held 657,876 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $78.78 million, up from 338,994 at the end of the previous reported quarter. Brookside Capital Management Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $3.54 billion market cap company. The stock increased 2.95% or $2.7 during the last trading session, reaching $94.3. About 491,376 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since January 22, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Brookside Capital Management Llc, which manages about $1.58B US Long portfolio, decreased its stake in Mulesoft Inc by 426,782 shares to 890,689 shares, valued at $17.94M in 2017Q3, according to the filing. It also reduced its holding in Godaddy Inc by 184,859 shares in the quarter, leaving it with 1.49M shares, and cut its stake in Regenxbio Inc.

More notable recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: Ft.com which released: “Puma Biotechnology shares jump as breast-cancer drug approved” on July 17, 2017, also Marketwatch.com with their article: “Puma Biotech stock surges 50% on favorable FDA release for breast cancer drug” published on May 22, 2017, Seekingalpha.com published: “Puma Biotechnology Continues To Thrive Despite European Debacle” on November 07, 2017. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) were released by: Seekingalpha.com and their article: “Puma Biotechnology Faces Balance Sheet Anxiety” published on November 10, 2017 as well as Seekingalpha.com‘s news article titled: “Puma Biotech Stock Offers Opportunity To Cash In On Its Maiden Product Launch” with publication date: August 15, 2017.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Puma Biotechnology Inc has $164 highest and $36 lowest target. $119’s average target is 26.19% above currents $94.3 stock price. Puma Biotechnology Inc had 49 analyst reports since August 27, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of PBYI in report on Wednesday, April 19 with “Outperform” rating. The company was maintained on Thursday, September 22 by Credit Suisse. The rating was maintained by J.P. Morgan on Tuesday, August 1 with “Buy”. The stock has “Buy” rating by Citigroup on Tuesday, May 23. Cowen & Co maintained Puma Biotechnology, Inc. (NASDAQ:PBYI) on Thursday, November 9 with “Buy” rating. Barclays Capital maintained the shares of PBYI in report on Friday, November 10 with “Overweight” rating. Stifel Nicolaus maintained Puma Biotechnology, Inc. (NASDAQ:PBYI) rating on Wednesday, August 9. Stifel Nicolaus has “Buy” rating and $11000 target. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Hold” rating by RBC Capital Markets on Thursday, September 14. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The rating was maintained by Cowen & Co on Tuesday, May 23 with “Market Perform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: